Breaking News

Autolus Therapeutics Explores the Feasibility of Adopting Cellares’ Cell Shuttle Platform

Will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications.

Author Image

By: Charlie Sternberg

Associate Editor

Autolus Therapeutics, a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen programmed T cell therapies, has announced plans to assess the feasibility of Cellares’ Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenage, UK. Cellares’ Cell Shuttle platform integrates all unit operations for CAR T manufacturing into a single-use, closed, pre-sterilized cartridge operated on a fully automated platf...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters